1. Academic Validation
  2. Crystal structure of human kynurenine aminotransferase II

Crystal structure of human kynurenine aminotransferase II

  • J Biol Chem. 2008 Feb 8;283(6):3567-3573. doi: 10.1074/jbc.M708358200.
Qian Han 1 Howard Robinson 2 Jianyong Li 3
Affiliations

Affiliations

  • 1 Department of Biochemistry, Virginia Tech University, Blacksburg, Virginia 24061.
  • 2 Biology Department, Brookhaven National Laboratory, Upton, New York 11973.
  • 3 Department of Biochemistry, Virginia Tech University, Blacksburg, Virginia 24061. Electronic address: [email protected].
Abstract

Human kynurenine aminotransferase II (hKAT-II) efficiently catalyzes the transamination of knunrenine to kynurenic acid (KYNA). KYNA is the only known endogenous antagonist of N-methyl-D-aspartate (NMDA) receptors and is also an antagonist of 7-nicotinic acetylcholine receptors. Abnormal concentrations of brain KYNA have been implicated in the pathogenesis and development of several neurological and psychiatric diseases in humans. Consequently, enzymes involved in the production of brain KYNA have been considered potential regulatory targets. In this article, we report a 2.16 A crystal structure of hKAT-II and a 1.95 A structure of its complex with kynurenine. The protein architecture of hKAT-II reveals that it belongs to the fold-type I pyridoxal 5-phosphate (PLP)-dependent enzymes. In comparison with all subclasses of fold-type I-PLP-dependent enzymes, we propose that hKAT-II represents a novel subclass in the fold-type I enzymes because of the unique folding of its first 65 N-terminal residues. This study provides a molecular basis for future effort in maintaining physiological concentrations of KYNA through molecular and biochemical regulation of hKAT-II.

Figures